Xentria Advances XTMAB-16 in Pulmonary Sarcoidosis
Chicago, Illinois, September 1, 2026 Xentria, Inc., a clinical-stage biotherapeutics company, has announced its next-stage clinical development plan for...
Neuroinflammation
Advertisement
Novartis Remibrutinib Cuts Relapses in Phase III MS Trials
Basel, Switzerland, September 1, 2026 Novartis has announced positive topline results from the Phase III REMODEL-1 and REMODEL-2 trials,...
Cellenkos Wins FDA Fast Track for CK0803 in ALS
Houston, Texas, Aug 27, 2026 Cellenkos, Inc. has received FDA Fast Track designation for CK0803, an investigational allogeneic, cord...
AC Immune Advances NLRP3 Inhibitor ACI-19764 in Phase 1
LAUSANNE, Switzerland, August 20, 2026 AC Immune SA announced positive preliminary Phase 1 clinical data for ACI-19764, its wholly...
INmune Bio Reports Q2 2026 Results and Pipeline Progress
BOCA RATON, Fla., August 6, 2026 INmune Bio Inc. reported its second quarter 2026 financial results while highlighting significant...
Advertisements
Annexon Reports Rapid GBS Responses with Tanruprubart in FORWARD Study
BRISBANE, Calif., August 6, 2026 Annexon, Inc. announced encouraging early clinical results from the ongoing FORWARD open-label study, with...
BioVie Advances Parkinson’s Program with Phase 2 Success
CARSON CITY, Nev., August 6, 2026 BioVie Inc. announced positive topline results from its Phase 2 SUNRISE-PD trial, demonstrating...
CervoMed Shares Neflamapimod Development Update
BOSTON, August 5, 2026 CervoMed announced that its management team will participate in a fireside chat and investor meetings...
Tiziana Life Sciences Reports Positive Foralumab Data in Third MSA Patient
BOSTON, July 31, 2026 Tiziana Life Sciences announced new quantitative PET imaging results from the third patient with Multiple...
INmune Targets Brain Injury-Linked Alzheimer’s
BOCA RATON, Fla., July 15, 2026 INmune Bio announced the publication of a peer-reviewed preclinical study in the Journal...
Advertisement
